J. Harris

发表

Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615.

K. Fu, P. Levine, A. Cmelak, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group.

B. Jeremic, L. Collette, J. Pignon, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Predictive classifier for intensive treatment of head and neck cancer

M. Parmar, J. Pignon, V. Grégoire, 2020, Cancer.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group.

B. Jeremic, L. Collette, J. Pignon, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Multi-institutional Trial of IMRT for Early Stage Oropharyngeal Cancer: Acceleration via Simultaneously Incorporated Boost (SIB) (RTOG 00-22)

Christopher U. Jones, A. Garden, K. Ang, 2008 .

Phase II Trial of Neoadjuvant/Adjuvant Imatinib Mesylate (IM) for Advanced Primary and Metastatic/Recurrent Operable Gastrointestinal Stromal Tumor (GIST) – early results of RTOG 0132

G. Demetri, B. Eisenberg, M. Heinrich, 2011 .

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Christopher U. Jones, E. Sturgis, P. Harari, 2019, The Lancet.

Phase II Randomized Trial of Postoperative Chemoradiation Plus Cetuximab for High-risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234)

K. Ang, P. Harari, J. Myers, 2009 .

Increased Oral Mucositis after IMRT versus Non-IMRT when Combined with Cetuximab and Cisplatin or Docetaxel for Head and Neck Cancer: Preliminary Results of RTOG 0234

K. Ang, P. Harari, S. Bentzen, 2008 .

Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer.

J. Pignon, V. Grégoire, J. Bourhis, 2019, Oral oncology.

NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer

R. Ferris, Q. Le, L. Mell, 2021, Cancers.

Concomitant boost radiation and concurrent cisplatin for advanced head and neck carcinomas: preliminary results of a phase II trial of the RTOG (99-14)

Christopher U. Jones, A. Garden, R. Weber, 2002 .

Human papillomavirus and survival of patients with oropharyngeal cancer.

K. Ang, R. Weber, C. Chung, 2010, The New England journal of medicine.

Emotional well‐being does not predict survival in head and neck cancer patients

K. Ang, J. Coyne, T. Pajak, 2008, Cancer.

A phase II study of submandibular gland transfer prior to radiation for prevention of radiation-induced xerostomia in head-and-neck cancer (RTOG 0244).

K. Ang, J. Jacobs, Anand K. Sharma, 2012, International journal of radiation oncology, biology, physics.

Institutional clinical trial accrual volume and survival of patients with head and neck cancer.

Quynh-Thu Le, Qian Wu, Mitchell Machtay, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.

A. Garden, Q. Zhang, Q. Le, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Sue S Yom, Wade L Thorstad, Adam S Garden, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225.

A. Garden, K. Ang, P. Xia, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234)

M. Suntharalingam, J. Cooper, E. Sturgis, 2016, Cancer.

Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00-22).

Walter R. Bosch, Avraham Eisbruch, Jones, 2010, International journal of radiation oncology, biology, physics.

Final results of local-regional control and late toxicity of RTOG 9003: a randomized trial of altered fractionation radiation for locally advanced head and neck cancer.

Christopher U. Jones, A. Garden, K. Ang, 2014, International journal of radiation oncology, biology, physics.

Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: a phase II trial of the radiation therapy oncology group (RTOG 99-14).

Jones, K., Christopher U. Jones, 2008, International journal of radiation oncology, biology, physics.

Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14.

Christopher U. Jones, A. Garden, R. Weber, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety of nivolumab added to chemoradiotherapy platforms for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504.

W. Curran, R. Ferris, Q. Le, 2022, International journal of radiation oncology, biology, physics.

Comparison Between IMRT and 3D CRT in Laryngeal Cancer Patients Treated on RTOG 0522

K. Ang, Q. Zhang, G. Shenouda, 2013 .

Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665

G. Demetri, B. Eisenberg, M. Heinrich, 2009, Journal of surgical oncology.

Phase II Study of External Irradiation and Weekly Paclitaxel for Nonmetastatic, Unresectable Pancreatic Cancer: RTOG-98-12

B. Erickson, R. Abrams, J. Paradelo, 2004, American journal of clinical oncology.

Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.

Christopher U. Jones, A. Garden, P. Harari, 2016, International journal of radiation oncology, biology, physics.

Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer.

Christopher U. Jones, R. Weber, Q. Zhang, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.

P. Harari, C. Chung, Q. Zhang, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.

K. Ang, C. Chung, Q. Zhang, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.

K. Ang, W. Curran, E. Horwitz, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Disadvantage of men living alone participating in Radiation Therapy Oncology Group head and neck trials.

A. Garden, J. Coyne, T. Pajak, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant radiation therapy, androgen deprivation, and docetaxel for high‐risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621

K. Badiozamani, D. Beyer, H. Sandler, 2017, Cancer.

Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.

K. Ang, P. Harari, Q. Zhang, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of tumor angiogenesis measured with microvessel density (MVD) as a prognostic indicator in nasopharyngeal carcinoma: results of RTOG 9505.

K. Ang, K. Fu, N. Weidner, 2005, International journal of radiation oncology, biology, physics.

The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial

Anurag K. Singh, J. Weidhaas, C. Chung, 2017, JAMA oncology.

Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03.

K. Ang, J. Erler, T. Pajak, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high‐risk, high‐grade, soft tissue sarcomas of the extremities and body wall

D. Ettinger, B. Eisenberg, T. Delaney, 2010, Cancer.

Validation of NRG oncology/RTOG‐0129 risk groups for HPV‐positive and HPV‐negative oropharyngeal squamous cell cancer: Implications for risk‐based therapeutic intensity trials

R. Weber, Q. Zhang, S. Yom, 2019, Cancer.

Pathologic complete response and survival outcomes in patients with localized soft tissue sarcoma treated with neoadjuvant chemoradiotherapy or radiotherapy: Long-term update of NRG Oncology RTOG 9514 and 0630.

D. Ettinger, W. Curran, B. Eisenberg, 2017 .

79 : Phase II Multi-institutional Study of IMRT for Oropharyngeal Cancer (RTOG 00-22): Early Results

A. Garden, K. Ang, G. Sanguineti, 2006 .

Final report of RTOG 9610, a multi‐institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck

S. Spencer, K. Ang, W. Spanos, 2008, Head & neck.

The impact of age on outcome in phase III NRG Oncology/RTOG trials of radiotherapy (XRT) +/- systemic therapy in locally advanced head and neck cancer.

Christopher U. Jones, A. Garden, R. Weber, 2021, Journal of geriatric oncology.

Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.

M. Suntharalingam, Q. Zhang, J. Barnholtz-Sloan, 2021, Oral oncology.

Risk stratification after recurrence of human papillomavirus (HPV)‐related and non‐HPV‐related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522

M. Birrer, Q. Le, H. Bahig, 2021, Head & neck.

Reply to B. O'Sullivan et Al.

A. Garden, A. El‐Naggar, Q. Zhang, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522.

Christopher U. Jones, A. Garden, K. Ang, 2015, International Journal of Radiation Oncology, Biology, Physics.

Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial.

P. Xia, N. Lee, S. Yom, 2023, The Lancet. Oncology.

Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024.

A. Garden, K. Ang, R. Weber, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RTOG 90-03: Final Report

Christopher U. Jones, A. Garden, K. Ang, 2012 .

Results of Radiation Therapy Oncology Group 97-03—A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck: Long-term Results and Late Toxicities

Christopher U. Jones, A. Garden, J. Cooper, 2007 .

Role of chemotherapy in 5 000 patients with head and neck cancer treated by curative surgery: a subgroup analysis of the Meta-Analysis of Chemotherapy in Head and Neck Cancer

J. Pignon, V. Grégoire, Q. Le, 2020 .

Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy: The NRG/RTOG 9514 and 0630 Nonrandomized Clinical Trials.

D. Ettinger, W. Curran, B. Eisenberg, 2023, JAMA oncology.

Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.

W. Curran, R. Ferris, Q. Le, 2018 .

Phase II Multi-Institutional Study of IMRT ± Chemotherapy for Nasopharyngeal Carcinoma (RTOG 0225): Preliminary Results

A. Garden, K. Ang, N. Lee, 2007 .

Predictive classifier for intensive treatment of head and neck cancer

M. Parmar, J. Pignon, V. Grégoire, 2020, Cancer.

Long-term Outcomes of Bevacizumab and Chemoradiation for Locoregionally Advanced Nasopharyngeal Carcinoma

A. Garden, J. Mechalakos, P. Harari, 2023, JAMA network open.

Safety Evaluation of Nivolumab Concomitant With Platinum-Based Chemoradiation therapy for Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504

W. Curran, R. Ferris, Q. Le, 2018 .

p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC).

K. Ang, P. Harari, C. Chung, 2013 .

Phase II Study of Paclitaxel and Cisplatin in Combination with Split Course Concomitant Hyperfractionated Re-Irradiation in Patients with Recurrent Squamous Cell Cancer of the Head and Neck: Results of RTOG 99-11

K. Ang, W. Curran, E. Horwitz, 2005 .

Mature results of Radiation Therapy Oncology Group (RTOG) Trial 9615 using intra-arterial cisplatin (IA-P) and concurrent radiation therapy (RT) for stage IV-T4 head/neck (H/N) squamous cell carcinoma (SCCa)

K. Fu, P. Levine, A. Cmelak, 2005 .

Radiotherapy with Durvalumab vs. Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer and a Contraindication to Cisplatin: Phase II Results of NRG-HN004

S. Yom, A. Minn, L. Mell, 2022, International Journal of Radiation Oncology*Biology*Physics.

Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.

A. Garden, C. Jones, J. Cooper, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504.

W. Curran, R. Ferris, Q. Le, 2019, Journal of Clinical Oncology.

Correlation of High-Risk Soft Tissue Sarcoma Biomarker Expression Patterns with Outcome following Neoadjuvant Chemoradiation

Q. Zhang, D. Kirsch, T. Delaney, 2018, Sarcoma.

NRG Oncology HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.

Steven S. Chang, V. Lowe, S. Kappadath, 2021 .

RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.

S. Spencer, W. Spanos, R. Meredith, 2001, International journal of radiation oncology, biology, physics.

Phase II Randomized Trial of Surgery Followed by Chemoradiation Plus Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234)

K. Ang, P. Harari, J. Myers, 2007 .

1914MO Randomized phase II study of radiation therapy and paclitaxel with pazopanib or placebo: NRG-RTOG 0912

P. Xia, C. Chung, N. Lee, 2020 .

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Christopher U. Jones, E. Sturgis, P. Harari, 2019, The Lancet.

Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.

Christopher U. Jones, A. Garden, P. Harari, 2016, International journal of radiation oncology, biology, physics.

Long-term update of NRG/RTOG 0522: a randomized phase III trial of concurrent radiation and cisplatin with or without cetuximab in locoregionally advanced head and neck cancer.

A. Garden, R. Weber, J. Galvin, 2022, International journal of radiation oncology, biology, physics.